Skip to main content
Latest news
Browse specialties
Breast cancer Genitourinary cancers Lung & thoracic cancers
In focus
Next-generation sequencing: Emerging biomarkers in thyroid and NSCLCs ctDNA and bladder cancer: Current understanding and beyond ROS1 fusion-positive NSCLC NSCLC driver mutations: Discussing the importance of RET, ALK and ROS1 alterations in NSCLC Early-stage NSCLC management: Surgery, targeted treatment and immunotherapy ALK fusion-positive NSCLC: International approaches to management RET fusion-positive NSCLC: Informing on the use of pralsetinib for patients with RET fusion-positive, advanced NSCLC COVID-19 & cancer
Conferences
SABCS 2022 ESMO 2022 2022 ASCO Annual Meeting
About us
Medicine Matters Oncology
EXTENDED SEARCH
Top

04-10-2019 | Castration-resistant prostate cancer | Video | Article

Researcher comment: Cabazitaxel a new third-line option in mCRPC

print
PRINT
insite
SEARCH

Ronald de Wit tells us why the CARD trial results are likely to change the paradigm for the treatment of metastatic castration-resistant prostate cancer (3:58).

External Content

Click Play to display this content and agree to third party cookies. (>)

Update your current cookie settings.

Read the transcript

print
PRINT
  • » This content is intended only for healthcare providers and was made possible by educational funding provided by F. Hoffmann-La Roche Ltd.

Related content

02-10-2019 | Castration-resistant prostate cancer | Video | Article

Expert comment: The CARD trial

30-09-2019 | Castration-resistant prostate cancer | Conference coverage | News

CARD results support cabazitaxel use in mCRPC

20-09-2019 | Castration-resistant prostate cancer | News

Adding carboplatin to cabazitaxel benefits men with mCRPC

20-09-2017 | FDA | News

Copanlisib, low-dose cabazitaxel receive FDA go ahead
Image Credits